ranolazine

Known as: Renolazine, 1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-(2-hydroxy- 3-(2-methoxyphenoxy)propyl)-, Ranolazine [Chemical/Ingredient] 
An orally available, piperazine derivative with anti-anginal and potential antineoplastic activities. Ranolazine's mechanism of action for its anti… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
RATIONALE Previously, we demonstrated that a deoxycorticosterone acetate (DOCA)-salt hypertensive mouse model produces cardiac… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
INTRODUCTION One form of the hereditary long-QT syndrome, LQT3-Delta KPQ, is associated with sustained inward sodium current… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
CONTEXT Ranolazine is a novel antianginal agent that reduces ischemia in patients with chronic angina but has not been studied in… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
BACKGROUND Ranolazine, a piperazine derivative, reduces ischemia via inhibition of the late phase of the inward sodium current… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2006
Highly Cited
2006
OBJECTIVES The purpose of this study was to determine if ranolazine improves angina in stable coronary patients with persisting… (More)
  • figure 2
  • table 3
  • table 5
Is this relevant?
Highly Cited
2006
Highly Cited
2006
BACKGROUND Ventricular repolarization and contractile function are frequently abnormal in ventricular myocytes from human failing… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
OBJECTIVES The primary objective of the Monotherapy Assessment of Ranolazine In Stable Angina (MARISA) trial was to determine the… (More)
  • table 3
  • figure 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
BACKGROUND Ranolazine is a novel antianginal agent capable of producing antiischemic effects at plasma concentrations of 2 to 6… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
Highly Cited
2004
Highly Cited
2004
The new anti-anginal drug ranolazine causes a slight (<10 milliseconds) prolongation of the QT interval, raising the concern that… (More)
Is this relevant?
Highly Cited
1996
Highly Cited
1996
BACKGROUND Ranolazine is a novel antianginal agent that may reduce symptoms without affecting hemodynamics and has shown cardiac… (More)
Is this relevant?